Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dana Horakova

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Therapeutic Advances in Neurological Disorders|January 14, 2015
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useEva Havrdova, Dana Horakova, Ivana Kovarova
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|September 24, 2019
Automated Assessment of Oral Diadochokinesis in Multiple Sclerosis Using a Neural Network Approach: Effect of Different Syllable Repetition ParadigmsKriss Rozenstoks, Michal Novotny, Dana Horakova, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|March 14, 2020
Comments and Corrections Corrections to "Automated Assessment of Oral Diadochokinesis in Multiple Sclerosis Using a Neural Network Approach: Effect of Different Syllable Repetition Paradigms"Kriss Rozenstoks, Michal Novotny, Dana Horakova, et al.
BMC Neurology|March 9, 2012
Clinical correlates of grey matter pathology in multiple sclerosisDana Horakova, Tomas Kalincik, Jana Blahova Dusankova, et al.
European Neurology|August 8, 2016
Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)Klara Novotna, Lukas Sobisek, Dana Horakova, et al.
Therapeutics and Clinical Risk Management|October 31, 2017
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development ProgramEva Havrdova, Jeffrey A Cohen, Dana Horakova, et al.
Plos One|November 21, 2012
Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort studyTomas Kalincik, Manuela Vaneckova, Michaela Tyblova, et al.
Development, Growth & Differentiation|October 4, 2014
Effect of FGFR inhibitors on chicken limb developmentDana Horakova, Petra Cela, Pavel Krejci, et al.
European Journal of Neurology|January 11, 2022
Pregnancy-induced brain magnetic resonance imaging changes in women with multiple sclerosisTomas Uher, Eva Kubala Havrdova, Karolina Vodehnalova, et al.
Biomed Research International|June 9, 2020
Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple SclerosisAdam Pudlac, Andrea Burgetova, Petr Dusek, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Therapeutic Advances in Neurological Disorders|January 14, 2015
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useEva Havrdova, Dana Horakova, Ivana Kovarova
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|September 24, 2019
Automated Assessment of Oral Diadochokinesis in Multiple Sclerosis Using a Neural Network Approach: Effect of Different Syllable Repetition ParadigmsKriss Rozenstoks, Michal Novotny, Dana Horakova, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|March 14, 2020
Comments and Corrections Corrections to "Automated Assessment of Oral Diadochokinesis in Multiple Sclerosis Using a Neural Network Approach: Effect of Different Syllable Repetition Paradigms"Kriss Rozenstoks, Michal Novotny, Dana Horakova, et al.
BMC Neurology|March 9, 2012
Clinical correlates of grey matter pathology in multiple sclerosisDana Horakova, Tomas Kalincik, Jana Blahova Dusankova, et al.
European Neurology|August 8, 2016
Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)Klara Novotna, Lukas Sobisek, Dana Horakova, et al.
Therapeutics and Clinical Risk Management|October 31, 2017
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development ProgramEva Havrdova, Jeffrey A Cohen, Dana Horakova, et al.
Plos One|November 21, 2012
Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort studyTomas Kalincik, Manuela Vaneckova, Michaela Tyblova, et al.
Development, Growth & Differentiation|October 4, 2014
Effect of FGFR inhibitors on chicken limb developmentDana Horakova, Petra Cela, Pavel Krejci, et al.
European Journal of Neurology|January 11, 2022
Pregnancy-induced brain magnetic resonance imaging changes in women with multiple sclerosisTomas Uher, Eva Kubala Havrdova, Karolina Vodehnalova, et al.
Biomed Research International|June 9, 2020
Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple SclerosisAdam Pudlac, Andrea Burgetova, Petr Dusek, et al.
Pageof 18